Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELLOMAK: Lacutamab in Advanced T-cell Lymphoma
2023-507777-18-00Phase 2Completed
- Sponsor
- Innate Pharma
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, open-label trial of lacutamab in Sézary syndrome (SS) and cutaneous T-cell lymphoma (CTCL) (2 arms), sponsored by Innate Pharma. Primary endpoint: Objective response rate (ORR). Started Apr 2024; status: completed.
02
Drugs
lacutamab
03
Conditions
Sézary syndrome (SS)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on 2023-507777-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507777-18-00.